Personalized Genomics Market By Product Type (Consumables, Instruments, Services), By Technology (Next-Generation Sequencing (NGS), PCR, Microarray, CRISPR), By Application (Genetic Testing, Pharmacogenomics, Oncology, Rare Diseases), By End-User (Hospitals, Research Institutes, Diagnostic Laboratories), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Personalized Genomics Market was valued at USD 13.0 billion in 2024-e and will surpass USD 20.5 billion by 2030; growing at a CAGR of 7.9% during 2025 - 2030.

The personalized genomics market is expanding rapidly, driven by advancements in technology and increasing demand for tailored healthcare solutions. Personalized genomics involves analyzing an individual's genetic profile to provide customized insights for disease prevention, diagnosis, and treatment. This approach has revolutionized fields such as genetic testing, oncology, and pharmacogenomics, enabling healthcare providers to deliver precise and effective medical interventions. The growing awareness of genetic predispositions and the rising prevalence of chronic diseases are further fueling the adoption of personalized genomics globally.

Technological innovations, particularly in next-generation sequencing (NGS) and CRISPR gene-editing technologies, are major drivers of market growth. These advancements have made genetic analysis more accessible, cost-effective, and reliable, thereby expanding its applications across various healthcare domains. With increasing investments in research and development, as well as rising consumer interest in personalized health insights, the personalized genomics market is poised for sustained growth in the coming years.

Consumables Product Type is Largest Owing to High Demand in Genetic Testing and Research

The consumables product type is the largest segment in the personalized genomics market, owing to their essential role in genetic testing and research processes. Consumables such as reagents, test kits, and sample preparation materials are critical components for genomic analysis, enabling accurate and efficient testing in various applications, including oncology and rare disease diagnosis. These products are used extensively in laboratories, hospitals, and research institutions, making them indispensable in the field of personalized genomics.

The high consumption rate of these products, combined with their recurring demand, contributes significantly to the segment's dominance. Furthermore, the continuous development of advanced consumables tailored to next-generation sequencing and PCR technologies has enhanced their efficiency and reliability, driving their widespread adoption. As genetic testing becomes increasingly routine in healthcare, the consumables segment is expected to maintain its leading position in the market.

Next-Generation Sequencing (NGS) Technology is Largest Owing to High Precision and Broad Applications

Next-generation sequencing (NGS) is the largest technology segment in the personalized genomics market, owing to its unparalleled precision and versatility in genetic analysis. NGS enables rapid and comprehensive sequencing of entire genomes or targeted regions, making it a cornerstone technology for applications such as genetic testing, oncology, and rare disease diagnosis. Its ability to provide detailed insights into genetic variations has revolutionized personalized medicine, allowing for more accurate diagnosis and tailored treatment plans.

The widespread adoption of NGS is further driven by continuous advancements in sequencing platforms, which have made the technology more affordable and accessible. The growing number of clinical studies utilizing NGS and its increasing use in pharmacogenomics and prenatal testing underscore its critical role in personalized genomics. As the demand for high-throughput and precise genomic analysis continues to rise, NGS is expected to remain the leading technology in this market.

Oncology Application is Largest Owing to Rising Cancer Incidence and Demand for Targeted Therapies

The oncology application is the largest segment in the personalized genomics market, driven by the rising global incidence of cancer and the growing demand for targeted therapies. Personalized genomic tools play a crucial role in identifying genetic mutations and biomarkers associated with different types of cancer, enabling the development of precision therapies tailored to individual patients. Genomic profiling in oncology allows healthcare providers to determine the most effective treatment strategies, minimizing side effects and improving patient outcomes.

Advancements in genetic testing and sequencing technologies have significantly enhanced the ability to detect cancer at an early stage, further fueling the adoption of personalized genomics in oncology. The increasing focus on precision oncology by healthcare providers and pharmaceutical companies underscores the importance of this application, which is expected to drive significant growth in the personalized genomics market.

Diagnostic Laboratories End-User is Fastest Growing Owing to Expanded Testing Capabilities

Diagnostic laboratories are the fastest-growing end-user segment in the personalized genomics market, owing to their expanded capabilities in genetic testing and analysis. Laboratories are at the forefront of adopting advanced technologies such as NGS and PCR to provide accurate and efficient genomic testing services. With the rising demand for personalized health insights, diagnostic laboratories are increasingly becoming key players in delivering genetic testing solutions to healthcare providers and patients.

The growth of this segment is further fueled by partnerships between laboratories and biotechnology companies, which are driving the development of innovative diagnostic solutions. The increasing availability of direct-to-consumer genetic testing through diagnostic laboratories has also contributed to the segment's rapid growth. As the need for advanced diagnostic services continues to rise, diagnostic laboratories are expected to play an increasingly central role in the personalized genomics market.

North America Region is Largest Owing to Technological Leadership and Robust Research Infrastructure

North America is the largest region in the personalized genomics market, owing to its technological leadership, strong research infrastructure, and high adoption rate of advanced genomic technologies. The region is home to some of the world's leading biotechnology companies, research institutions, and diagnostic laboratories, which are driving innovation in personalized genomics. The United States, in particular, has made significant investments in genomics research, fostering the development and commercialization of cutting-edge technologies like NGS and CRISPR.

The region's robust healthcare infrastructure and growing emphasis on personalized medicine have further contributed to its dominance in the market. With increasing consumer awareness of genetic testing and a supportive regulatory environment, North America is expected to maintain its leadership position in the personalized genomics market.

Leading Companies and Competitive Landscape

Leading companies in the personalized genomics market include Illumina, Thermo Fisher Scientific, Qiagen, and 23andMe, which are recognized for their expertise in genomic analysis technologies and services. These companies are at the forefront of developing innovative products, such as advanced sequencing platforms and direct-to-consumer genetic testing kits, that cater to the growing demand for personalized healthcare solutions.

The competitive landscape is characterized by ongoing research and development, as well as strategic collaborations and acquisitions aimed at expanding product portfolios and market reach. Companies are also focusing on improving the accessibility and affordability of genomic technologies, further driving the adoption of personalized genomics in both clinical and research settings. As the market continues to evolve, competition is expected to intensify, with both established players and new entrants contributing to the growth of personalized genomics.

Recent Developments:

• In December 2024, Illumina launched a new NGS platform designed to enhance personalized medicine applications.
• In November 2024, Thermo Fisher Scientific announced a collaboration to develop CRISPR-based personalized genomic solutions.
• In October 2024, Qiagen introduced a new genetic testing kit for rare disease diagnostics, broadening its portfolio.
• In September 2024, 23andMe announced updates to its direct-to-consumer genetic testing services to include pharmacogenomics insights.
• In August 2024, BGI Genomics expanded its global presence by establishing a new genetic testing facility in Europe.

List of Leading Companies:

• Illumina, Inc.
• Thermo Fisher Scientific
• Qiagen
• Roche Diagnostics
• Agilent Technologies
• Bio-Rad Laboratories
• Pacific Biosciences
• BGI Genomics
• PerkinElmer, Inc.
• Oxford Nanopore Technologies
• Myriad Genetics
• 23andMe, Inc.
• Invitae Corporation
• Genomics England
• GeneDx

Report Scope: